Vaccine value profile for enterotoxigenic Escherichia coli (ETEC)

Area of Science:

• Vaccinology
• Infectious Diseases
• Public Health

Background:

• Enterotoxigenic Escherichia coli (ETEC) is a primary cause of diarrhea in young children in low-resource settings and a common issue for travelers.
• ETEC infections lead to significant mortality, morbidity, and long-term developmental impacts in children.
• The emergence of antimicrobial resistance necessitates novel strategies to combat bacterial pathogens like ETEC.

Purpose of the Study:

• To assess the public health, economic, and societal value of enterotoxigenic Escherichia coli (ETEC) vaccines.
• To inform potential strategies for ETEC vaccine development and deployment.
• To identify research and knowledge gaps in the field of ETEC vaccines.

Main Methods:

• A Vaccine Value Profile (VVP) was developed by a multidisciplinary working group.
• The VVP utilized existing, publicly available data on ETEC and vaccine candidates.
• Expert consensus was used to assess the value and identify knowledge gaps.

Main Results:

• The lead ETEC vaccine candidate, ETVAX, has demonstrated field efficacy in travelers and is undergoing efficacy testing in infants.
• Phase 3 trials for ETVAX in infants and travelers are planned, with potential licensing within 5-8 years.
• A standalone ETEC vaccine is cost-effective, with potential for combination with other childhood vaccines to maximize protection.

Conclusions:

• An effective ETEC vaccine offers substantial public health benefits, particularly for vulnerable populations.
• ETEC vaccines can reduce antibiotic use, thereby mitigating antimicrobial resistance.
• Strategic development and combination approaches can enhance the cost-effectiveness and impact of ETEC vaccination.